Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

Abstract Background BPaL, a 6 month oral regimen composed of bedaquiline, pretomanid, and linezolid for treating extensively drug-resistant tuberculosis (XDR-TB) is a potential alternative for at least 20 months of individualized treatment regimens (ITR). The ITR has low tolerability, treatment adhe...

Full description

Bibliographic Details
Main Authors: S. E. J. van de Berg, P. T. Pelzer, A. J. van der Land, E. Abdrakhmanova, A. Muhammad Ozi, M. Arias, S. Cook-Scalise, G. Dravniece, A. Gebhard, S. Juneja, R. Handayani, D. Kappel, M. Kimerling, I. Koppelaar, S. Malhotra, B. Myrzaliev, B. Nsa, J. Sugiharto, N. Engel, C. Mulder, S. van den Hof
Format: Article
Language:English
Published: BMC 2021-07-01
Series:BMC Public Health
Subjects:
BPaL
Pretomanid
XDR-TB
Novel TB regimen
Acceptability
Feasibility
Online Access:https://doi.org/10.1186/s12889-021-11427-y

Internet

https://doi.org/10.1186/s12889-021-11427-y

Similar Items